{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:53:07Z","timestamp":1788713587844,"version":"build-2803163510"},"reference-count":133,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Kidney Health Dis"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review:<\/jats:title>\n                    <jats:p>Kidney disease is present in almost half of Canadian patients with type 2 diabetes (T2D), and it is also the most common first cardiorenal manifestation of T2D. Despite clear guidelines for testing, opportunities are being missed to identify kidney diseases, and many Canadians are therefore not receiving the best available treatments. This has become even more important given recent clinical trials demonstrating improvements in both kidney and cardiovascular (CV) endpoints with sodium-glucose cotransporter 2 (SGLT2) inhibitors and a nonsteroidal mineralocorticoid receptor antagonist, finerenone. The goal of this document is to provide a narrative review of the current evidence for the treatment of diabetic kidney disease (DKD) that supports this new standard of care and to provide practice points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sources of information:<\/jats:title>\n                    <jats:p>An expert panel of Canadian clinicians was assembled, including 9 nephrologists, an endocrinologist, and a primary care practitioner. The information the authors used for this review consisted of published clinical trials and guidelines, selected by the authors based on their assessment of their relevance to the questions being answered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Panelists met virtually to discuss potential questions to be answered in the review and agreed on 10 key questions. Two panel members volunteered as co-leads to write the summaries and practice points for each of the identified questions. Summaries and practice points were distributed to the entire author list by email. Through 2 rounds of online voting, a second virtual meeting, and subsequent email correspondence, the authors reached consensus on the contents of the review, including all the practice points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings:<\/jats:title>\n                    <jats:p>It is critical that DKD be identified as early as possible in the course of the disease to optimally prevent disease progression and associated complications. Patients with diabetes should be routinely screened for DKD with assessments of both urinary albumin and kidney function. Treatment decisions should be individualized based on the risks and benefits, patients\u2019 needs and preferences, medication access and cost, and the degree of glucose lowering needed. Patients with DKD should be treated to achieve targets for A1C and blood pressure. Renin-angiotensin-aldosterone system blockade and treatment with SGLT2 inhibitors are also key components of the standard of care to reduce the risk of kidney and CV events for these patients. Finerenone should also be considered to further reduce the risk of CV events and chronic kidney disease progression. Education of patients with diabetes prescribed SGLT2 inhibitors and\/or finerenone is an important component of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>No formal guideline process was used. The practice points are not graded and are not intended to be viewed as having the weight of a clinical practice guideline or formal consensus statement. However, most practice points are well aligned with current clinical practice guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20543581221150556","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T04:29:43Z","timestamp":1674620983000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Family & Community Medicine, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Girard","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Cumming School of Medicine, University of Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McFarlane","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Moist","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Nessim","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Jewish General Hospital, McGill University, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Soroka","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Centre, Nova Scotia Health, Halifax, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Stafford","sequence":"additional","affiliation":[{"name":"Fraser Health Division of Endocrinology, University of British Columbia, Surrey, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Steele","sequence":"additional","affiliation":[{"name":"Lakeridge Health, Whitby, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Division of Nephrology, St. Michael\u2019s Hospital, University of Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"bibr1-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.07.015"},{"key":"bibr2-20543581221150556","unstructured":"Public Health Agency of Canada. Highlights: diabetes in Canada: facts and figures from a public health perspective. https:\/\/www.canada.ca\/en\/public-health\/services\/chronic-diseases\/reports-publications\/diabetes\/diabetes-canada-facts-figures-a-public-health-perspective\/report-highlights.html. Published 2011. Accessed December 30, 2022."},{"key":"bibr3-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14074"},{"key":"bibr4-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.11.004"},{"key":"bibr5-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.10704"},{"key":"bibr6-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"bibr7-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"bibr8-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"bibr9-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.10.012"},{"key":"bibr10-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211032"},{"key":"bibr11-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203662"},{"key":"bibr12-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00530119"},{"key":"bibr13-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06190616"},{"key":"bibr14-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw452"},{"key":"bibr15-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1159\/000489913"},{"key":"bibr16-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62459-4"},{"key":"bibr17-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2021.10.002"},{"key":"bibr18-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2901"},{"key":"bibr19-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"bibr20-20543581221150556","unstructured":"Ingelheim B. A multicentre international randomized parallel group double-blind placebo-controlled Clinical Trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594110. Published February 2022. Accessed December 30, 2022."},{"key":"bibr21-20543581221150556","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"bibr22-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"bibr23-20543581221150556","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","journal-title":"Can J Diabetes"},{"key":"bibr24-20543581221150556","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2008","journal-title":"Can J Diabetes"},{"key":"bibr25-20543581221150556","volume":"27","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2003","journal-title":"Can J Diabetes"},{"key":"bibr26-20543581221150556","volume-title":"Poster presentation presented at Alberta College of Family Physicians Annual Scientific Assembly","author":"Garg D","year":"2018"},{"key":"bibr27-20543581221150556","unstructured":"Armstrong M, Weaver R, Pannu N. Prevalence and quality of care in chronic kidney disease. https:\/\/www.albertahealthservices.ca\/assets\/about\/scn\/ahs-scn-kh-ckd-report-2019.pdf. Published February 2019. Accessed December 30, 2022."},{"key":"bibr28-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17323"},{"key":"bibr29-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30104-3"},{"key":"bibr30-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2322"},{"key":"bibr31-20543581221150556","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i5.172"},{"key":"bibr32-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2020.08.001"},{"key":"bibr33-20543581221150556","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"bibr34-20543581221150556","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"bibr35-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.13.1555"},{"key":"bibr36-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004110919"},{"key":"bibr37-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"bibr38-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"bibr39-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.251"},{"key":"bibr40-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.11.007"},{"key":"bibr41-20543581221150556","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"bibr42-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30369-7"},{"key":"bibr43-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac040"},{"key":"bibr44-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30141-4"},{"key":"bibr45-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"bibr46-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"bibr47-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233."},{"issue":"10365","key":"bibr48-20543581221150556","first-page":"1788","volume":"2022","author":"The Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","journal-title":"Lancet Lond Engl"},{"key":"bibr49-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1177\/2054358120935701"},{"key":"bibr50-20543581221150556","doi-asserted-by":"publisher","DOI":"10.7326\/M19-2610"},{"key":"bibr51-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30078-5"},{"key":"bibr52-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05424-4"},{"key":"bibr53-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab497"},{"key":"bibr54-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa133"},{"key":"bibr55-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"bibr56-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"bibr57-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"bibr58-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"bibr59-20543581221150556","unstructured":"Spertus J. Canagliflozin impact on health status, quality of life, and functional status in heart failure-CHIEF-HF. American Heart Association. https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2021\/11\/12\/00\/23\/chief-hf. Published 2021. Accessed December 30, 2022."},{"key":"bibr60-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868"},{"key":"bibr61-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5"},{"key":"bibr62-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"bibr63-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042007"},{"key":"bibr64-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"bibr65-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14539"},{"key":"bibr66-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"bibr67-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116"},{"key":"bibr68-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa294"},{"key":"bibr69-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30256-6"},{"key":"bibr70-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.77"},{"key":"bibr71-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.272328"},{"key":"bibr72-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.04488"},{"key":"bibr73-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2017.12.002"},{"key":"bibr74-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"bibr75-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.657957"},{"key":"bibr76-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10360"},{"key":"bibr77-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000091"},{"key":"bibr78-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08526"},{"key":"bibr79-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.016"},{"key":"bibr80-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"bibr81-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.01.017"},{"key":"bibr82-20543581221150556","author":"Rossing P","journal-title":"Diabetes Care"},{"key":"bibr83-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.65"},{"key":"bibr84-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.67"},{"key":"bibr85-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.356"},{"key":"bibr86-20543581221150556","unstructured":"Janssen Inc. INVOKANA product monograph. https:\/\/www.janssen.com\/canada\/sites\/www_janssen_com_canada\/files\/prod_files\/live\/invokana_cpm.pdf. Published May 2020. Accessed December 30, 2022."},{"key":"bibr87-20543581221150556","unstructured":"AstraZeneca Canada Inc. FORXIGA product monograph. https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/forxiga-product-monograph-en.pdf. Published August 2021. Accessed December 30, 2022."},{"key":"bibr88-20543581221150556","unstructured":"Boehringer Ingelheim (Canada) Ltd. JARDIANCE product monograph. https:\/\/www.boehringer-ingelheim.ca\/sites\/ca\/files\/documents\/jardiancepmen.pdf. Published October 2021. Accessed December 30, 2022."},{"key":"bibr89-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02480221"},{"key":"bibr90-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.0939"},{"key":"bibr91-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.067"},{"key":"bibr92-20543581221150556","volume":"372","author":"Albasri A","year":"2021","journal-title":"BMJ"},{"key":"bibr93-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr94-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"bibr95-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218739"},{"key":"bibr96-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002187"},{"key":"bibr97-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa232"},{"key":"bibr98-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuac026"},{"key":"bibr99-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.018"},{"key":"bibr100-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.210831"},{"key":"bibr101-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12651018"},{"key":"bibr102-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"bibr103-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410853"},{"key":"bibr104-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32135-X"},{"key":"bibr105-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15688"},{"key":"bibr106-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.7446"},{"key":"bibr107-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.04.011"},{"key":"bibr108-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"bibr109-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004.pub3"},{"key":"bibr110-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)02957-6"},{"key":"bibr111-20543581221150556","volume":"43","author":"American Diabetes Association. Addendum. 9","year":"2020","journal-title":"Diabetes Care"},{"key":"bibr112-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1177\/2042098621989134"},{"key":"bibr113-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13611"},{"key":"bibr114-20543581221150556","volume":"44","author":"American Diabetes Association","year":"2021","journal-title":"Diabetes Care"},{"key":"bibr115-20543581221150556","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1224-P"},{"key":"bibr116-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1194"},{"key":"bibr117-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0275-6"},{"key":"bibr118-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14075"},{"key":"bibr119-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"key":"bibr120-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01004-2"},{"key":"bibr121-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"bibr122-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782"},{"key":"bibr123-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031"},{"key":"bibr124-20543581221150556","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"bibr125-20543581221150556","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","journal-title":"Can J Diabetes"},{"key":"bibr126-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-64"},{"key":"bibr127-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211003683"},{"key":"bibr128-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18169"},{"key":"bibr129-20543581221150556","unstructured":"Canadian Agency for Drugs and Technologies in Health. Canagliflozin (invokana) for type 2 diabetes mellitus. https:\/\/www.ncbi.nlm.nih.gov\/nlmcatalog\/101680394. Published 2015. Accessed December 30, 2022."},{"key":"bibr130-20543581221150556","unstructured":"Novo Nordisk A\/S. Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819153. Published 2022. Accessed December 30, 2022."},{"key":"bibr131-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2020.09.005"},{"key":"bibr132-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"bibr133-20543581221150556","doi-asserted-by":"publisher","DOI":"10.1186\/2054-3581-1-5"}],"container-title":["Canadian Journal of Kidney Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581221150556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20543581221150556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581221150556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:21:19Z","timestamp":1777389679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20543581221150556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":133,"alternative-id":["10.1177\/20543581221150556"],"URL":"https:\/\/doi.org\/10.1177\/20543581221150556","relation":{},"ISSN":["2054-3581","2054-3581"],"issn-type":[{"value":"2054-3581","type":"print"},{"value":"2054-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20543581221150556"}}